Kindred Biosciences is a drug manufacturers - specialty & generic business based in the US. Kindred Biosciences shares (KIN) are listed on the NASDAQ and all prices are listed in US Dollars. Kindred Biosciences employs 63 staff and has a trailing 12-month revenue of around $5.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.83 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $9.20 |
| 200-day moving average | $6.64 |
| Wall St. target price | $9.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.02 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.83 from 2021-05-28
| 1 week (2024-07-15) | N/A |
|---|---|
| 1 month (2024-06-22) | N/A |
| 3 months (2024-04-22) | N/A |
| 6 months (2024-01-22) | N/A |
| 1 year (2023-07-22) | N/A |
|---|---|
| 2 years (2022-07-22) | N/A |
| 3 years (2021-07-26) | 9.11 |
| 5 years (2019-07-26) | 6.72 |
| Revenue TTM | $5.8 million |
|---|---|
| Gross profit TTM | $-1,162,000 |
| Return on assets TTM | -23.11% |
| Return on equity TTM | -50.36% |
| Profit margin | 0% |
| Book value | $1.76 |
| Market Capitalization | $420.5 million |
TTM: trailing 12 months
We're not expecting Kindred Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Kindred Biosciences's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kindred Biosciences's is 1.3152. This would suggest that Kindred Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Kindred Biosciences, Inc. , a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California. As of August 27, 2021, Kindred Biosciences, Inc.
Learn these options trading strategies to lock in profits and get acquainted with a new asset class.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.